Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets.

Jain R, Jain D, Liu Q, Bartosinska B, Wang J, Schumann D, Kauschke SG, Eickelmann P, Piemonti L, Gray NS, Lammert E.

Diabetologia. 2013 Jun;56(6):1350-5. doi: 10.1007/s00125-013-2877-1. Epub 2013 Mar 9.

PMID:
23475368
2.

CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a tail-anchored protein in the endoplasmic reticulum (ER) of insulinoma cells.

Brambillasca S, Altkrueger A, Colombo SF, Friederich A, Eickelmann P, Mark M, Borgese N, Solimena M.

J Biol Chem. 2012 Dec 7;287(50):41808-19. doi: 10.1074/jbc.M112.376558. Epub 2012 Oct 9.

3.

Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter.

Grempler R, Augustin R, Froehner S, Hildebrandt T, Simon E, Mark M, Eickelmann P.

FEBS Lett. 2012 Feb 3;586(3):248-53. doi: 10.1016/j.febslet.2011.12.027. Epub 2011 Dec 30.

4.

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, Eickelmann P, Mark M.

Diabetes Obes Metab. 2012 Jan;14(1):94-6. doi: 10.1111/j.1463-1326.2011.01518.x. Epub 2011 Nov 13.

PMID:
21985693
5.

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P.

Diabetes Obes Metab. 2012 Jan;14(1):83-90. doi: 10.1111/j.1463-1326.2011.01517.x. Epub 2011 Nov 13.

PMID:
21985634
6.

Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation.

Grempler R, Leicht S, Kischel I, Eickelmann P, Redemann N.

FEBS Lett. 2007 Dec 22;581(30):5885-90. Epub 2007 Dec 3.

7.

Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.

Weber D, Berger C, Eickelmann P, Antel J, Kessler H.

J Med Chem. 2003 May 8;46(10):1918-30.

PMID:
12723954
8.

Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Lammerich HP, Busmann A, Kutzleb C, Wendland M, Seiler P, Berger C, Eickelmann P, Meyer M, Forssmann WG, Maronde E.

Br J Pharmacol. 2003 Apr;138(8):1431-40.

9.

Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3.

Weber D, Berger C, Heinrich T, Eickelmann P, Antel J, Kessler H.

J Pept Sci. 2002 Aug;8(8):461-75.

PMID:
12212809
10.

Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies.

Schulz WA, Krummeck A, Rösinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Dräger BJ, Sies H.

Pharmacogenetics. 1997 Jun;7(3):235-9.

PMID:
9241663
11.
12.

Free radicals in toxicology: redox cycling and NAD(P)H:quinone oxidoreductase.

Schulz WA, Eickelmann P, Sies H.

Arch Toxicol Suppl. 1996;18:217-22. No abstract available.

PMID:
8678798
14.

Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line.

Eickelmann P, Schulz WA, Rohde D, Schmitz-Dräger B, Sies H.

Biol Chem Hoppe Seyler. 1994 Jul;375(7):439-45.

PMID:
7945992
15.
16.
17.

Increase of beta-actin mRNA upon hypotonic perfusion of perfused rat liver.

Schulz WA, Eickelmann P, Hallbrucker C, Sies H, Häussinger D.

FEBS Lett. 1991 Nov 4;292(1-2):264-6.

Supplemental Content

Loading ...
Support Center